Terms: = Skin cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
72 results:
1. T antigen-specific CD8+ T cells associate with pd-1 blockade response in virus-positive Merkel cell carcinoma.
Hansen UK; Church CD; Carnaz Simões AM; Frej MS; Bentzen AK; Tvingsholm SA; Becker JC; Fling SP; Ramchurren N; Topalian SL; Nghiem PT; Hadrup SR
J Clin Invest; 2024 Jan; 134(8):. PubMed ID: 38618958
[TBL] [Abstract] [Full Text] [Related]
2. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant pd-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
3. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
6. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
[TBL] [Abstract] [Full Text] [Related]
7. Combined pd-1, BRAF and MEK inhibition in BRAF
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
8. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With clinical outcome Under pd-1 Blockade.
Gaißler A; Meldgaard TS; Heeke C; Babaei S; Tvingsholm SA; Bochem J; Spreuer J; Amaral T; Wagner NB; Klein R; Meier F; Garbe C; Eigentler TK; Pawelec G; Claassen M; Weide B; Hadrup SR; Wistuba-Hamprecht K
Front Immunol; 2022; 13():906352. PubMed ID: 35874702
[TBL] [Abstract] [Full Text] [Related]
9. Toripalimab (anti-pd-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.
Lian B; Si L; Chi ZH; Sheng XN; Kong Y; Wang X; Tian H; Li K; Mao LL; Bai X; Tang BX; Yan XQ; Li SM; Zhou L; Dai J; Tang XW; Ran FW; Yao S; Guo J; Cui CL
Ann Oncol; 2022 Oct; 33(10):1061-1070. PubMed ID: 35842199
[TBL] [Abstract] [Full Text] [Related]
10. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract] [Full Text] [Related]
11. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-pd-1.
McCulloch JA; Davar D; Rodrigues RR; Badger JH; Fang JR; Cole AM; Balaji AK; Vetizou M; Prescott SM; Fernandes MR; Costa RGF; Yuan W; Salcedo R; Bahadiroglu E; Roy S; DeBlasio RN; Morrison RM; Chauvin JM; Ding Q; Zidi B; Lowin A; Chakka S; Gao W; Pagliano O; Ernst SJ; Rose A; Newman NK; Morgun A; Zarour HM; Trinchieri G; Dzutsev AK
Nat Med; 2022 Mar; 28(3):545-556. PubMed ID: 35228752
[TBL] [Abstract] [Full Text] [Related]
12. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract] [Full Text] [Related]
13. A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma.
Koch EAT; Schaft N; Kummer M; Berking C; Schuler G; Hasumi K; Dörrie J; Schuler-Thurner B
Front Immunol; 2022; 13():785231. PubMed ID: 35185883
[TBL] [Abstract] [Full Text] [Related]
14. Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
Cristiani CM; Capone M; Garofalo C; Madonna G; Mallardo D; Tuffanelli M; Vanella V; Greco M; Foti DP; Viglietto G; Ascierto PA; Spits H; Carbone E
Front Immunol; 2022; 13():811131. PubMed ID: 35173725
[TBL] [Abstract] [Full Text] [Related]
15. Deconvolving clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-pd-1 Therapy.
Wang K; Patkar S; Lee JS; Gertz EM; Robinson W; Schischlik F; Crawford DR; Schäffer AA; Ruppin E
Cancer Discov; 2022 Apr; 12(4):1088-1105. PubMed ID: 34983745
[TBL] [Abstract] [Full Text] [Related]
16. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-pd-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract] [Full Text] [Related]
17. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract] [Full Text] [Related]
18. Baseline and early functional immune response is associated with subsequent clinical outcomes of pd-1 inhibition therapy in metastatic melanoma patients.
Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
[TBL] [Abstract] [Full Text] [Related]
19. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-pd-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
[TBL] [Abstract] [Full Text] [Related]
[Next]
